-
Posted by
Two Blokes May 15 -
Filed in
Stock
-
2 views
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) saw its shares jump 8% after it put out a midday update on its outlook, seeing strong medium-term growth. Annual revenue growth of 6% to 8% is expected, with 7% to 9% CAGR in core operating profit from 2024 to 2027.
